Intercept Pharmaceuticals, Inc. (NasdaqGM: ICPT)
Health Care · Biotechnology · US
$—
— today · — 1Y
Intercept Pharmaceuticals, Inc. (NasdaqGM: ICPT) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Intercept Pharmaceuticals, Inc. across four factors: quality 41/100, growth 66/100. Its strongest factor is growth.
ICPT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $317.68M
- P/E
- —
- EPS
- -1.48
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 341
- Next earnings
- —
About Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada. The company currently markets Ocaliva, a medication functioning as a farnesoid X receptor (FXR) agonist. This drug is approved for the treatment of primary biliary cholangitis (PBC) in adults, specifically when administered alongside ursodeoxycholic acid. Beyond its existing approved indications, Intercept is actively investigating Ocaliva's potential for additional uses, notably including nonalcoholic steatohepatitis (NASH). Concurrently, it is progressing other drug candidates through various clinical and preclinical stages of development. In a collaborative effort, the company holds a licensing agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. Intercept distributes its products through a dual approach, utilizing both its proprietary commercial organization and a network of external third-party distributors. The company was founded in 2002 and is headquartered in New York, New York.
- ISIN
- US45845P1084
- Founded
- 2002
- Listed since
- Oct 11, 2012
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.76 | +0.47% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.16 | -0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.72 | +1.35% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $553.13 | +1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.58 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.86 | +14.38% |
Figures last refreshed Aug 18, 2026.